The treatment of beva monoantigen anti-combined tymoazine is expected to improve the survival of GBM patients.

Glioblastoma (GBM) is the brain tumor with the worst prognosis.
currently believes that tymoamine (TMZ) and tumor electric field therapy can improve the overall survival rate (OS) of GBM.
beva monoantin (BEV) has been shown to improve progress-free survival in two clinical trials, AVAglio and RTOG 0825.
Japan in 2013 to use beval monoantigen for first-line treatment of GBM.
Nobuhiro Hata of Neurosurgery, Kyushe University School of Medical Sciences, Japan, and others analyzed the effects of tymoazine-combined beva monoantigen on the overall survival rate of GBM patients using clinical data from the treatment of GBM in Japan, published in the February 2020 issue of Journal of Neuro-Oncology.
study included 120 GBM patients from 2002 to 2018, divided into 3 groups according to treatment at different times: 19 in the pre-pre-TMZ group, 51 in the TMZ group, and 50 in the TMZ combined beva monoantigen (TMZ) group.
Results of the study were as follows: 1. The survival of GBM patients was significantly prolonged: the 2.3% and 27.8% survival rates of the two groups of patients were 5.3% and 27.8%, respectively;
1. Analysis of the total survival of patients with newly diagnosed glioblastoma who were in the pre-application group, the group of tymoxamine, and the group of patients with the combined beva monoantigroup of glioblastoma.
2. Beva monoantigen improved the efficacy of GBM patients who had not been fully removed: the median overall survival of the combined beva monoantigroups of termoazine and tymoazine was 10.1 and 16 months, respectively;
3. In patients with MGMT methylation, the medium overall survival period was significantly improved: the medium total survival of the pre-application group and the mid-level total survival of tymoamine group was 18.5 months and 28.1 months, respectively; In patients with MGMT non-methylation, the medium overall survival was significantly improved after the combined beva monoantigen, and the medium overall survival of the combined treatment group and the tymoamine group was 16.7 months and 12.2 months, respectively.
conclusions, the results suggest that early selective beva monoantigenothamine can prolong the overall survival of patients.
But the clinical data from single center, limited number of cases and long treatment time span are all shortcomings in research design, so more clinical data are needed to further evaluate the efficacy of beva monotherapy GBM.
: The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights- persons.
, editing, copying, cutting, recording, etc. without permission.
be used with a license, the source must also be indicated.
welcome to forward and share.
.